© 2012 Nature America, Inc. All rights reserved.
6 4 6 VOLUME 30 NUMBER 7 JULY 2012 nature biotechnology
R E V I E W
the Damon Runyon Cancer Research Foundation Fellowship (DRG-2017-09).
The authors would also like to thank M. Angelo for useful discussions
pertaining to the information in Table 1.
COMPETING FINANCIAL INTERESTS
The authors declare competing financial interests: details are available in the online
version of the paper.
Published online at http://www.nature.com/doifinder/10.1038/nbt.2283.
Reprints and permissions information is available online at http://www.nature.com/
1. Spencer, S.L. & Sorger, P.K. Measuring and modeling apoptosis in single cells. Cell
144, 926–939 (2011).
2. Spencer, S.L. et al. Non-genetic origins of cell-to-cell variability in TRAIL-induced
apoptosis. Nature 459, 428–432 (2009).
3. Vincent, M. Cancer: a de-repression of a default survival program common to all cells?
A life-history perspective on the nature of cancer. Bioessays 34, 72–82 (2012).
4. Greaves, M. & Maley, C.C. Clonal evolution in cancer. Nature 481, 306–313
5. Visvader, J.E. Cells of origin in cancer. Nature 469, 314–322 (2011).
6. Medema, J.P. & Vermeulen, L. Microenvironmental regulation of stem cells in
intestinal homeostasis and cancer. Nature 474, 318–326 (2011).
7. Wang, X. et al. A luminal epithelial stem cell that is a cell of origin for prostate
cancer. Nature 461, 495–500 (2009).
8. Knoepﬂer, P. Journal club. A cell biologist looks at the risk and promise of a new
insight into stem cells and cancer. Nature 457, 361 (2009).
9. Yang, J. et al. Intratumoral heterogeneity determines discordant results of diagnostic
tests for human epidermal growth factor receptor (HER) 2 in gastric cancer
specimens. Cell Biochem. Biophys. 62, 221–228 (2012).
10. Zhang, J., Yang, P.L. & Gray, N.S. Targeting cancer with small molecule kinase
inhibitors. Nat. Rev. Cancer 9, 28–39 (2009).
11. Taussig, D.C. et al. Leukemia-initiating cells from some acute myeloid leukemia
patients with mutated nucleophosmin reside in the CD34(-) fraction. Blood 115,
12. Yap, T.A. et al. Intratumor heterogeneity: seeing the wood for the trees. Sci. Transl.
Med. 4, 127ps10 (2012).
13. Gerlinger, M. et al. Intratumor heterogeneity and branched evolution revealed by
multiregion sequencing. N. Engl. J. Med. 366, 883–892 (2012).
14. Longo, D.L. Tumor heterogeneity and personalized medicine. N. Engl. J. Med. 366,
15. Cantor, H. et al. Characterization of subpopulations of T lymphocytes. I. Separation
and functional studies of peripheral T-cells binding different amounts of ﬂuorescent
anti-Thy 1.2 (theta) antibody using a ﬂuorescence-activated cell sorter (FACS).
Cell. Immunol. 15, 180–196 (1975).
16. Parks, D.R. et al. Antigen-speciﬁc identiﬁcation and cloning of hybridomas with a
ﬂuorescence-activated cell sorter. Proc. Natl. Acad. Sci. USA 76, 1962–1966 (1979).
17. Werner, M. et al. Microﬂuidic array cytometer based on refractive optical tweezers
for parallel trapping, imaging and sorting of individual cells. Lab Chip 11,
18. Wlodkowic, D. & Darzynkiewicz, Z. Rise of the micromachines: microﬂuidics and
the future of cytometry. Methods Cell Biol. 102, 105–125 (2011).
19. Liu, A.Y., Roudier, M.P. & True, L.D. Heterogeneity in primary and metastatic
prostate cancer as deﬁned by cell surface CD proﬁle. Am. J. Pathol. 165,
20. Bragado, P. et al. Analysis of marker-deﬁned HNSCC subpopulations reveals a
dynamic regulation of tumor initiating properties. PLoS ONE 7, e29974 (2012).
21. Choijamts, B. et al. CD133
cancer stem cell-like cells derived from uterine
carcinosarcoma (malignant mixed Mullerian tumor). Stem Cells 29, 1485–1495
22. Bonnet, D. & Dick, J.E. Human acute myeloid leukemia is organized as a hierarchy
that originates from a primitive hematopoietic cell. Nat. Med. 3, 730–737
23. Cho, R.W. & Clarke, M.F. Recent advances in cancer stem cells. Curr. Opin. Genet.
Dev. 18, 48–53 (2008).
24. Lobo, N.A. et al. The biology of cancer stem cells. Annu. Rev. Cell Dev. Biol. 23,
25. Nguyen, L.V. et al. Cancer stem cells: an evolving concept. Nat. Rev. Cancer 12,
26. Irish, J.M. et al. Single cell proﬁling of potentiated phospho-protein networks in
cancer cells. Cell 118, 217–228 (2004).
27. Kotecha, N. et al. Single-cell proﬁling identiﬁes aberrant STAT5 activation in myeloid
malignancies with speciﬁc clinical and biologic correlates. Cancer Cell 14, 335–343
28. Irish, J.M. et al. B-cell signaling networks reveal a negative prognostic human
lymphoma cell subset that emerges during tumor progression. Proc. Natl. Acad.
Sci. USA 107, 12747–12754 (2010).
29. Palazzo, A.L. et al. Association of reactive oxygen species-mediated signal
transduction with in vitro apoptosis sensitivity in chronic lymphocytic leukemia
B cells. PLoS ONE 6, e24592 (2011).
30. Perez, O.D. & Nolan, G.P. Resistance is futile: assimilation of cellular machinery
by HIV-1. Immunity 15, 687–690 (2001).
31. Krutzik, P.O. & Nolan, G.P. Intracellular phospho-protein staining techniques for
ﬂow cytometry: monitoring single cell signaling events. Cytometry A 55, 61–70
32. Sachs, K. et al. Causal protein-signaling networks derived from multiparameter
single-cell data. Science 308, 523–529 (2005).
33. Rosen, D.B. et al. Distinct patterns of DNA damage response and apoptosis correlate
with Jak/Stat and PI3kinase response proﬁles in human acute myelogenous
leukemia. PLoS ONE 5, e12405 (2010).
34. Krutzik, P.O. et al. High-content single-cell drug screening with phosphospeciﬁc
ﬂow cytometry. Nat. Chem. Biol. 4, 132–142 (2008).
35. Sachs, K. et al. Characterization of patient speciﬁc signaling via augmentation of
Bayesian networks with disease and patient state nodes. Conf. Proc. IEEE Eng.
Med. Biol. Soc. 2009, 6624–6627 (2009).
36. Sachs, K. et al. Learning signaling network structures with sparsely distributed data.
J. Comput. Biol. 16, 201–212 (2009).
37. Rosen, D.B. et al. Assessing signaling pathways associated with in vitro resistance
to cytotoxic agents in AML. Leuk. Res. 900–904 (2012).
38. Cesano, A. et al. Functional pathway analysis in acute myeloid leukemia using
single cell network proﬁling assay: effect of specimen source (bone marrow or
peripheral blood) on assay readouts. Cytometry B Clin. Cytom. 82, 158–172
39. Longo, D.M. et al. Single-cell network proﬁling of peripheral blood mononuclear
cells from healthy donors reveals age- and race-associated differences in immune
signaling pathway activation. J. Immunol. 188, 1717–1725 (2012).
40. Yates, J.R., Ruse, C.I. & Nakorchevsky, A. Proteomics by mass spectrometry:
approaches, advances, and applications. Annu. Rev. Biomed. Eng. 11, 49–79
41. Bandura, D.R. et al. Mass cytometry: technique for real time single cell multitarget
immunoassay based on inductively coupled plasma time-of-ﬂight mass spectrometry.
Anal. Chem. 81, 6813–6822 (2009).
42. Bendall, S.C. et al. Single-cell mass cytometry of differential immune and drug
responses across a human hematopoietic continuum. Science 332, 687–696
43. Qiu, P. et al. Extracting a cellular hierarchy from high-dimensional cytometry data
with SPADE. Nat. Biotechnol. 29, 886–891 (2011).
44. Newell, E.W. et al. Cytometry by time-of-ﬂight shows combinatorial cytokine
expression and virus-speciﬁc cell niches within a continuum of CD8+ T cell
phenotypes. Immunity 36, 142–152 (2012).
45. Behbehani, G. et al. Single cell mass cytometry adapted to measurements of the
cell cycle. Cytometry A (in the press).
46. Fienberg, H.G., Simonds. E.F. Fantl. W.J. Nolan. G.P. & Bodenmiller, B. A platinum-
based covalent viability reagent for single-cell mass cytometry. Cytometry A 81,
47. Hoshida, Y. et al. Integrative transcriptome analysis reveals common molecular
subclasses of human hepatocellular carcinoma. Cancer Res. 69, 7385–7392
48. Hoshida, Y. et al. Gene expression in ﬁxed tissues and outcome in hepatocellular
carcinoma. N. Engl. J. Med. 359, 1995–2004 (2008).
49. Mullighan, C.G. et al. Genomic analysis of the clonal origins of relapsed acute
lymphoblastic leukemia. Science 322, 1377–1380 (2008).
50. Notta, F. et al. Evolution of human BCR-ABL1 lymphoblastic leukaemia-initiating
cells. Nature 469, 362–367 (2011).
51. Kapranov, P., Ozsolak, F. & Milos, P.M. Proﬁling of short RNAs using Helicos single-
molecule sequencing. Methods Mol. Biol. 822, 219–232 (2012).
52. Nagalakshmi, U. et al. The transcriptional landscape of the yeast genome deﬁned
by RNA sequencing. Science 320, 1344–1349 (2008).
53. Ozsolak, F. & Milos, P.M. RNA sequencing: advances, challenges and opportunities.
Nat. Rev. Genet. 12, 87–98 (2011).
54. Wang, Z., Gerstein, M. & Snyder, M. RNA-Seq: a revolutionary tool for transcriptomics.
Nat. Rev. Genet. 10, 57–63 (2009).
55. Ley, T.J. et al. DNA sequencing of a cytogenetically normal acute myeloid leukaemia
genome. Nature 456, 66–72 (2008).
56. Mardis, E.R. et al. Recurring mutations found by sequencing an acute myeloid
leukemia genome. N. Engl. J. Med. 361, 1058–1066 (2009).
57. Ding, L. et al. Clonal evolution in relapsed acute myeloid leukaemia revealed by
whole-genome sequencing. Nature 481, 506–510 (2012).
58. Walter, M.J. et al. Clonal architecture of secondary acute myeloid leukemia.
N. Engl. J. Med. 366, 1090–1098 (2012).
59. Anderson, K. et al. Genetic variegation of clonal architecture and propagating cells
in leukaemia. Nature 469, 356–361 (2011).
60. Hou, Y. et al. Single-cell exome sequencing and monoclonal evolution of a JAK2-
negative myeloproliferative neoplasm. Cell 148, 873–885 (2012).
61. Xu, X. et al. Single-cell exome sequencing reveals single-nucleotide mutation
characteristics of a kidney tumor. Cell 148, 886–895 (2012).
62. Tang, F. et al. mRNA-Seq whole-transcriptome analysis of a single cell. Nat. Methods
6, 377–382 (2009).
63. Dalerba, P. et al. Single-cell dissection of transcriptional heterogeneity in human
colon tumors. Nat. Biotechnol. 29, 1120–1127 (2011).
64. Gibbs, K.D. Jr. et al. Decoupling of tumor-initiating activity from stable
immunophenotype in HoxA9-Meis1-driven AML. Cell Stem Cell 10, 210–217
© 2012 Nature America, Inc. All rights reserved.